Mantle Cell Lymphoma 2020 Roundtable Discussion

Mantle cell lymphoma (MCL) is a rare, often aggressive form of non-Hodgkin lymphoma that develops when the body makes abnormal B-cells, and it is typically diagnosed at a later stage of disease. In a follow up to last year’s expert discussion on MCL , Matthew Matasar, MD met with Jacqueline Claudia Barrientos, MD and Andrew Evens, DO, MSc, FACP to further review diagnosis and evaluation, appropriate treatment approaches for different patient populations, and day-to-day management of MCL.

Video 1: MCL Diagnosis and Staging

The panel reviews the steps taken during a patient’s initial evaluation for MCL, risk stratification in order to determine therapy options, and various options and benefits for testing.

Up Next

Video 1: MCL Diagnosis and Staging
Video 2: Current MCL Treatment Approaches
Video 3: Day-to-Day MCL Management

About the Panel

Dr. Matasar Photo

Matthew Matasar, MD

  • Moderator
  • Chief of the Medical Oncology Service
  • Memorial Sloan Kettering Cancer Center Bergen
Dr. Barrientos Photo

Jacqueline Claudia Barrientos, MD

  • Associate Professor
  • Northwell Health Cancer Institute
Dr. Evans Photo

Andrew M. Evens, DO, MSc, FACP

  • Professor of Medicine,
    Rutgers Robert Wood Johnson Medical School
  • Associate Director for Clinical Service,
    Rutgers Cancer Institute of Technology
  • Medical Director, Oncology Service Line,
    RWJBarnabas Health
Disclosures

Dr. Matasar reports relationships with Bayer, Daiichi Sankyo, Genentech, GlaxoSmithKline, Janssen, Juno Therapeutics, Merck, Pharmacyclics, Roche, Rocket Medical, Seattle Genetics and Teva.

Dr. Barrientos reports relationships with AstraZeneca, Bayer, Celgene, Gilead, Janssen, Oncternal, and Sandoz.

Dr. Evens reports relationships with Cota, Epizyme, the Leukemia & Lymphoma Society, MorphoSys, Mylteni, Novartis, OncLive, ORIEN, Pharmacyclics, Physician Education Resource, Research to Practice, Seattle Genetics, and Tesaro